EcoDrugPlus

Melatonin Receptor 1a A

Ensembl ID : ENSOSIG00000007463
Gene Symbol: MTNR1AA
1 Cross references
186 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSOSIG00000015965
Gene Symbol: MME
1 Cross references
233 Possible Orthologues:

Methionyl Aminopeptidase 2b

Ensembl ID : ENSOSIG00000015553
Gene Symbol: METAP2B
1 Cross references
220 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSOSIG00000004238
Gene Symbol: MAPK1
1 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSOSIG00000011683
Gene Symbol: MAPK10
1 Cross references
88 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSOSIG00000016364
Gene Symbol: MAPK11
1 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSOSIG00000017138
Gene Symbol: MAPK3
1 Cross references
197 Possible Orthologues:

Mitogen-Activated Protein Kinase 8a

Ensembl ID : ENSOSIG00000015169
Gene Symbol: MAPK8A
1 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSOSIG00000015093
Gene Symbol: MAPK8B
1 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSOSIG00000022353
Gene Symbol: MAP2K1
1 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2a

Ensembl ID : ENSOSIG00000009348
Gene Symbol: MAP2K2A
1 Cross references
212 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSOSIG00000001051
Gene Symbol: MAP3K11
1 Cross references
182 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).